190 related articles for article (PubMed ID: 18703707)
1. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy.
Au WY; Tam S; Fong BM; Kwong YL
Blood; 2008 Nov; 112(9):3587-90. PubMed ID: 18703707
[TBL] [Abstract][Full Text] [Related]
2. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia.
Au WY; Tam S; Fong BM; Kwong YL
Blood; 2006 Apr; 107(7):3012-3. PubMed ID: 16554490
[No Abstract] [Full Text] [Related]
3. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
[TBL] [Abstract][Full Text] [Related]
4. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
Shen ZX; Chen GQ; Ni JH; Li XS; Xiong SM; Qiu QY; Zhu J; Tang W; Sun GL; Yang KQ; Chen Y; Zhou L; Fang ZW; Wang YT; Ma J; Zhang P; Zhang TD; Chen SJ; Chen Z; Wang ZY
Blood; 1997 May; 89(9):3354-60. PubMed ID: 9129042
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
[TBL] [Abstract][Full Text] [Related]
6. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage.
Shen Y; Shen ZX; Yan H; Chen J; Zeng XY; Li JM; Li XS; Wu W; Xiong SM; Zhao WL; Tang W; Wu F; Liu YF; Niu C; Wang ZY; Chen SJ; Chen Z
Leukemia; 2001 May; 15(5):735-41. PubMed ID: 11368433
[TBL] [Abstract][Full Text] [Related]
7. Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.
Torka P; Al Ustwani O; Wetzler M; Wang ES; Griffiths EA
Blood Rev; 2016 May; 30(3):201-11. PubMed ID: 26709030
[TBL] [Abstract][Full Text] [Related]
8. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.
Kiguchi T; Yoshino Y; Yuan B; Yoshizawa S; Kitahara T; Akahane D; Gotoh M; Kaise T; Toyoda H; Ohyashiki K
Leuk Res; 2010 Mar; 34(3):403-5. PubMed ID: 19733394
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
Lam MS; Ignoffo RJ
Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
[No Abstract] [Full Text] [Related]
10. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
Chou WC; Dang CV
Curr Opin Hematol; 2005 Jan; 12(1):1-6. PubMed ID: 15604884
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
12. Arsenic-induced APL differentiation in cerebrospinal fluid.
Helwig A; Klemm M; Schüttig R; Röllig C; Wassilew N; Ehninger G; Illmer T
Leuk Res; 2007 May; 31(5):703-5. PubMed ID: 16876245
[TBL] [Abstract][Full Text] [Related]
13. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
Zhang P
J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia].
Ni J; Chen G; Shen Z; Li X; Liu H; Huang Y; Fang Z; Chen S; Wang Z; Chen L
Zhonghua Xue Ye Xue Za Zhi; 1997 May; 18(5):250-3. PubMed ID: 15622757
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide: safety issues and their management.
Au WY; Kwong YL
Acta Pharmacol Sin; 2008 Mar; 29(3):296-304. PubMed ID: 18298894
[TBL] [Abstract][Full Text] [Related]
16. [Oral administration of arsenic trioxide induced molecular remission in relapsed acute promyelocytic leukemia].
Fukuda M
Rinsho Ketsueki; 2005 Nov; 46(11):1223-5. PubMed ID: 16440808
[TBL] [Abstract][Full Text] [Related]
17. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
Muto A; Kizaki M; Kawamura C; Matsushita H; Fukuchi Y; Umezawa A; Yamada T; Hata J; Hozumi N; Yamato K; Ito M; Ueyama Y; Ikeda Y
Leukemia; 2001 Aug; 15(8):1176-84. PubMed ID: 11480559
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ
Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.
Rojewski MT; Körper S; Schrezenmeier H
Leuk Lymphoma; 2004 Dec; 45(12):2387-401. PubMed ID: 15621751
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide.
Hirayama Y; Koyama R; Nagai T; Ohta H; Kondo A; Ishikawa K; Ishitani K; Matsunaga T; Sakamaki S; Niitsu Y
Intern Med; 2001 Nov; 40(11):1136-9. PubMed ID: 11757771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]